Site map

Pages

• Home
• The LabEx
  • Who we are?
  • Governance
• Research
  • KQ1 – How can target activity be modulated through antibody binding?
  • KQ2 – How can antibody activity be optimised by adjusting format?
  • KQ3 – How can antibody efficacy be increased using combinations?
  • KQ4 – How can antibody administration be improved?
• Training
• Health
  • Clinical
  • Socioeconomic
  • Teaching tools
    • Clip Biomedicaments Polepharma
    • Movie “Les biomédicaments”
• Contact us
• Terms and conditions
• Site map

Posts by category

• Category: News
  • Questioning the relevance of non-human primates in the preclinical studies of cytolytic antibodies
  • 7th AIS: Harnessing the immune system with therapeutic antibodies – June 24&25
  • MAbImprove part of the 103 LAbEx selected for a 5-years extension!
  • Eight LabEx teams join their strengths in the battle against breast cancer
  • MAbTope: a Method for Improved Epitope Mapping
  • Nobel Prize in Medicine 2018
  • Nobel Prize in Chemistry 2018
  • APRÈS LE DIAGNOSTIC, UNE PISTE DE TRAITEMENT DE LA POLYARTHRITE RHUMATOÏDE: PROJET ATHRITIS R&D
  • Allocations doctorales 2016 : Listes des sujets de thèses anticorps
  • PhD Project 2014 “Design of a method for in silico maturation of antibodies”
  • Category: Events
    • AIS 2018 : TARGETS FOR MABS INNOVATIVE APPROACHES FOR THEIR DISCOVERY & VALIDATION
    • MASTER CLASSES DE L’IMMUNOTHÉRAPIE
    • Assises 2017: Antibody-Drug Conjugates
    • MAbDelivery Industrial Workshop
    • industrial workshop
    • Antibody Biosimilars, May 28th 2013, Tours, France
    • European Congress of Immunology Glasgow, Scotland | 5 – 8 September, 2012
    • “Therapeutic Antibodies and Infectious Diseases” Conference, November 20th-22nd in Tours, France
  • Category: Press review
    • Bioterrorisme : un traitement contre l’empoisonnement à la ricine – Le Magazine de la santé
  • Category: Recruitment
    • Development of new immunoconjugates for HER2-positive breast cancers
    • 2 Years Post-doctoral fellowship in Montpellier
    • PhD Projects 2015
    • Call for proposals 2015: New research team & group leader
    • PhD Project 2014 “Modulation of the functions of human dendritic cells by Mabs specific of type C lectine receptors “
    • PhD Project 2014 “Regulation of FcRn expression during tumorigenesis: Impact in the treatment with therapeutic antibodies”
    • PhD Project 2014 “Identification of new targets involved in the Cetuximab molecular mechanism in colorectal cancer”
    • PhD Project 2014 “New formats of recombinant antibody libraries”
    • PhD Project 2014 “Analysis of isoforms from the tyrosine kinase receptor HER4: towards a therapeutic targeting using isoform-specific antibodies in cancerology”
    • PhD project 2014 “Innovative strategies for bioconjugation towards therapeutic and imaging applications”
    • Job offer: MAbImprove scientific coordinator
    • Call for proposals 2014: New research team & group leader
    • IRCM: Postdoctoral proposition
    • New research (Cancer) teams in Montpellier (France)
    • Post-graduate researcher/postdoctoral position in Tours (GICC/CEPR)
  • Category: Research
    • First-in-­human phase I study for SurgiMab’s molecule SGM-­101 launched in Montpellier Cancer Institute.

Teams/Research groups

• Lymphocytes differentiation, tolerance and metabolism: basis for immunotherapy
• Genetic and immunopathology of inflammatory osteoarticular diseases.
• Respiratory infection & Immunity
• Neurogenomics and neuronal physiopathology
• Pharmacology of therapeutic antibodies in Humans
• FRAME: Fc Receptors, Antibodies and MicroEnvironment
• Tumor Microenvironment and Resistance to Therapies Lab
• Genomic Plasticity and Phenotypic Expression
• SENSOR : Energy Sensors and reproductive signalisation
• Leukemic niches and redox metabolism
• Innovation Moléculaire et Thérapeutique
• Baculovirus et Thérapie
• IMGT®, the international ImMunoGeneTics information system®
• Receptor Cytokine and Signaling
• Deficits of Reward, GPCRs and Sociability
• Biology and Bioinformatics of Signaling Systems
• Biomédicaments antiparasitaires
• Aerosoltherapy and biologics for respiratory diseases
• Proteolytic Mechanisms in Inflammation
• Radiobiology and Targeted Radiotherapy
• Immunotargeting and Radiobiology in Oncology
• Functional screening and targeting in cancer
• Proteases, Microenvironment and Cancer
• Drug resistance and new cancer treatment
• Immunity and Cancer
• Oncogenesis and Immunotherapy
• Neuroreceptors, dynamics and function
• Dendritic Cells, Immuno-modulation and Grafts

Platforms

• BIOCUBE Institute
• Médico-économie des anticorps
• Preclinical models platform
• Proteomics Imaging and Molecular Interaction Plateau (PP2I)
• Chemistry-Physics of antibodies
• Montpellier Cancer Institute (ICM)
• Immunovigilance of antibodies
• Small Animal Imaging (Platform IPABS)
• Monitoring centre and Biological follow-up of therapeautic Antibodies (CePiBAc)
• Biological Resource Centre (CRB)
• Clinical Investigation Centre (CIC Tours)
• Clinical Investigation Centre (CIC Montpellier)
• Small Animal Imaging centre (CIPA)

Past events

• 7TH INTERNATIONAL SYMPOSIUM ON KALLIKREINS AND KALLIKREIN-RELATED PEPTIDASES (ISK2017)
• Therapeutic Monoclonal Antibodies for Respiratory Diseases: Current challenges and perspectives
• Therapeutic antibodies and anaphylaxis
• Therapeutic Antibodies and Infectious Diseases

Partnerships

• KYMERIS SANTE
• iMAb
• MAbSilico SAS
• McSAF
• SurgiMAb
• CYNBIOSE RESPIRATORY
• REPROPHARM VET
• IGYXOS

Industrial Workshops

• Assises 2018 : Targets for Mabs Innovative Approaches for their Discovery & Validation
• Assises 2017: Antibody-Drug Conjugates: Design & Development for Therapy and Imaging in and beyond Cancer
• Assises 2016: Current and next generation Antibody formats
• Assises 2015: MAbDelivery
• Assises 2014 : MAbDosing
• Assises 2013 : Antibody biosimilars